Four pharmacies, by name, and permission to use a fifth
The Terms carry a paragraph that most of this roster would not write. It says the company provides access to prescription fulfilment services offered by the following pharmacies, and then lists four of them with their legal names: Absolute Pharmacy, LLC; Belmar Pharma Solutions; The Pharmacy Hub; and TMC Acquisition, LLC doing business as Tailor Made Compounding.
The next sentence goes further. It states that the company and its providers fully honour patient freedom, and that if a provider writes you a prescription you always have the option to instruct them to transmit it to the pharmacy of your choice. Most compounded sellers here are built the opposite way — the medication is the product and the pharmacy is a captive part of it.
The prescribing side is named too, though at the group level: Wellness Provider Group, P.A., described in the privacy policy as an independent medical group with a network of licensed practitioners. Naming the group is not the same as naming the person, but it is more than a phrase about board-certified clinicians.
Every price is an as-low-as price, and the site says why without saying what
Each of the two drugs has a product page offering two formats — a weekly injection and a daily rapid-dissolve tablet — and each format carries a figure prefixed with the words as low as. That prefix is doing real work. The homepage prints a footnote reading that all treatments require a medical evaluation and that pricing varies by plan and subscription.
So the seller has told you there are plans, and told you there is a subscription, and published neither. We searched the semaglutide page, the tirzepatide page and the homepage for the words membership, programme fee and consultation fee, and found none of them. The word subscription appears exactly once on the site we read: in the footnote explaining that it changes the price.
That is a different failure from silence. A seller that says nothing about a membership leaves you to ask. A seller that names a subscription as a pricing variable and never prices it has told you the number on the page is incomplete and left you no way to complete it. Bon Health puts four commitment tiers in a table with the total on each row; Cora Health publishes every tier and says in so many words that there is no starting-at figure. Here there is only a starting-at figure.
What our rows carry is what the page prints, with that footnote attached to each one. Read them as a floor, not as a rate.
Two named doctors who are not your doctor
The about page has an executive team of three — a founder and chief executive with an IT background, a chief operating officer, a chief technology officer — and then a section headed Advisory Board with two physicians in it. One is board certified in anaesthesiology and anti-aging medicine and is described as sitting on the medical board. The other is a Manhattan gynecologist, described as a healthcare advisor.
Both are real names you could look up, and that is worth something. Neither is presented as prescribing for patients here, and neither specialty is the one you would expect on a GLP-1 prescription. So on the question a reader is actually asking — who is going to be responsible for my dose — the answer is still the group name and not a person.
We score this the same way we scored Gimme Care, which names a physician on an author page under a pharmacy operations title. A name attached to a governance role is not a prescriber disclosure. It reads like one at a glance, which is exactly why it is worth writing down.
The oral tablet is a real option here, and it is not the cheap one
Both drugs are offered as a weekly injection or a daily rapid-dissolve tablet, priced separately on the same page, which makes this one of the few sellers here where the format decision is visible before an intake rather than after one.
The direction of the difference is worth flagging, because readers often assume a pill is the cheaper route. It is not, on either drug. The tablet figure is meaningfully higher than the injection figure for semaglutide, and higher again for tirzepatide. Both figures are on our row.
This is compounded medication throughout — there is no brand-name lane here, and the pages say so, with the not-FDA-approved disclaimer printed beneath the product copy.
Where it operates, and how old the paperwork is
There is no state list. The homepage and the about page both say available in most states, and the Terms say the services may not be available in your state. We read the homepage, the about page, both product pages, the Terms and the privacy policy; none of them enumerates anything. Our row records no states rather than inferring coverage from that phrasing.
The company does publish what many here will not: a full corporate postal address in Tampa and a phone number, in both its Terms and its privacy policy, alongside the legal entity Nu Image Medical, Inc. If you need to send a company a letter, this is one of the ones you can.
A smaller thing, and it belongs in the same paragraph: the copyright line on the Terms reads 2024. The pharmacy list in that document is the best disclosure on this site, and it is sitting in a file that has not been dated in two years.
Nu Image Medical's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $99/mo"Choose your Semaglutide format / Semaglutide Injections / As low as $99/mo". The page intro reads "Explore cash-pay semaglutide, a GLP-1 medication, as a weekly injection from $99/month". ⛔ The homepage footnote applies: "All treatments require a medical evaluation. Pricing varies by plan and subscription" — and no plan or subscription table is published anywhere on the site. | September 2026source |
| Semaglutide (compounded-oral) | $269/mo"Semaglutide RDT / Rapid-dissolve tablets / As low as $269/mo", the second of two formats offered on the same product page. Same unpublished-plan caveat: "Pricing varies by plan and subscription". | September 2026source |
| Tirzepatide (compounded) | $269/mo"Tirzepatide / Injections / As low as $269/mo", with the page intro reading "Explore cash-pay tirzepatide, a dual-pathway GLP-1/GIP medication, as a weekly injection from $269/month". Same unpublished-plan caveat: "Pricing varies by plan and subscription". | September 2026source |
| Tirzepatide (compounded-oral) | $314/mo"Tirzepatide RDT / Rapid-dissolve tablets / As low as $314/mo". Same unpublished-plan caveat: "Pricing varies by plan and subscription". | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 83 providers reviewed here are paid partners today; the other 79 are not. See how this works.
See Nu Image Medical's current price →Good fit if
- Readers who want to know which pharmacy will fill the prescription before they start, and want it in the Terms rather than in marketing copy.
- Buyers who want the option of sending the prescription to their own pharmacy, which this seller states in writing.
- People weighing a weekly injection against a daily tablet who want both priced on the same page.
- Anyone who wants a real postal address and a phone number attached to the company they are buying from.
Look elsewhere if
- Anyone who needs to know what they will actually be charged. Every figure here is an as-low-as number under a footnote saying pricing varies by plan and subscription, and neither is published.
- Readers who want the membership question answered. QuickMD states three separate times that no membership applies; Bon Health says the medication price is the final price.
- Buyers who need their state confirmed before starting. Wisp enumerates its states route by route; Direct Meds names the two it cannot serve.
- Patients who want a named prescribing clinician rather than an advisory board. Cora Health names its medical director and two clinicians beside him.
- Anyone after a brand-name GLP-1. This is a compounded-only catalogue.
How this review was verified
- Re-read the homepage, the about page, both product pages, the Terms and the privacy policy on 6 September 2026, rather than carrying any figure across from the research file that nominated this seller.
- Printed the status, byte size and effective URL of every fetch and compared the effective path to the requested one, so a same-host redirect could not be mistaken for a page.
- Ran a nonsense path against this host in the same run as every read. It returned 404 at 1,910 bytes every time, which is how a real 404 on this host is shaped.
- Extracted every price from a Python html.parser pass over text nodes only, with residual markup asserted absent — so no figure quoted here came out of markup that renders nowhere.
- Searched all three commercial pages for membership, programme fee and consultation fee before recording the membership status as unstated, and quoted the homepage footnote that names a subscription without pricing it.
- Recorded no price for the two non-GLP-1 programmes sold beside these drugs, and wrote the reason into the roster row: the cheaper of the two would otherwise have entered a GLP-1 comparison as one of the lowest figures on this site.
- Screened the legal entity against FDA's live warning-letter record with a positive control and a nonsense-string negative control in the same run. No letter to this entity appeared; untitled letters are published separately and were not searched, so this is not a claim that no FDA action exists.